Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06944834

A Study on the Safety and Functionality of the Implantable Wireless Brain-Computer Interfaces for Motor Rehabilitation

The objective of this study is to evaluate the safety and efficacy of minimally invasive, wireless brain-machine interface system (WRS) in patients with paralysis (resulting from spinal cord injuries, brainstem strokes, amyotrophic lateral sclerosis, or other motor neuron diseases causing complete or incomplete quadriplegia) or bilateral upper limb amputations. By leveraging brain-machine interface alternative technology, participants can use brain signals to control external devices (such as moving cursors, wheelchairs, robotic arms, WeChat Mini Programs, and other physical assistive devices), thereby improving their motor function and quality of life.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

The objective of this study is to evaluate the safety and efficacy of minimally invasive, wireless brain-machine interface system (WRS) in patients with paralysis (resulting from spinal cord injuries, brainstem strokes, amyotrophic lateral sclerosis, or other motor neuron diseases causing complete or incomplete quadriplegia) or bilateral upper limb amputations. By leveraging brain-machine interface alternative technology, participants can use brain signals to control external devices (such as moving cursors, wheelchairs, robotic arms, WeChat Mini Programs, and other physical assistive devices), thereby improving their motor function and quality of life.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-65 years;
  • Patients with complete or incomplete quadriplegia due to spinal cord injury, brainstem stroke, amyotrophic lateral sclerosis (ALS), or other motor neuron diseases, or those with bilateral upper limb amputations;
  • Normal motor cortex function confirmed by neurological assessment;
  • Muscle strength of bilateral or unilateral upper limbs ≤ Grade 3;
  • Patients who have received standardized treatment and met diagnostic criteria for at least 12 months before screening, with stable disease status for ≥6 months;
  • Expected lifespan ≥12 months;
  • Normal cognitive function;
  • Normal hearing and vision, or corrected vision to normal with standard lenses;
  • Patients with stable caregivers;
  • Willing to sign informed consent and able to comply with follow-up requirements.

Exclusion criteria

  • Patients with neuropsychiatric disorders or psychological impairments;
  • Patients with brain MRI findings showing hemorrhage, tumors, anatomical abnormalities, or distortions;
  • History of severe systemic diseases (e.g., cardiac, pulmonary, hepatic, renal, thyroid, gastrointestinal, or hematologic disorders), poorly controlled diabetes, or pregnancy in females;
  • History of infectious diseases (e.g., syphilis, HIV), severe traumatic brain injury, or major surgeries;
  • Presence of metal implants or devices (e.g., cochlear implants, pacemakers, neurostimulators, defibrillators), except for dental implants or other implants deemed non-interfering;
  • Surgical or anesthesia contraindications as determined by surgeons or anesthesiologists;
  • Morbid obesity (BMI >40);
  • Hearing impairment or uncorrectable visual deficits that would hinder prolonged computer monitor viewing;
  • Current participation in other clinical trials;
  • Other conditions considered unsuitable by investigators or medical staff.

Treatment and study plan

implant

Device

Implantation of the device and follow-up

Primary outcomes

  1. Adverse events

    Time frame: Within 6 months after implantation

    The incidence of adverse events associated with the device or surgical procedure

Secondary outcomes

  1. WRS Efficacy Assessment- Accuracy

    Time frame: 6 months after the implantation

    Validation of motor function improvement through cursor control performance metrics: the accuracy of of task list (number of correct items/ number of all items), the higher the better.

  2. WRS Efficacy Assessment- Path efficiency

    Time frame: 6 months after the implantation

    Validation of motor function improvement is demonstrated through cursor control performance metrics, particularly path efficiency (the ratio of optimal to actual movement path). Higher values indicate better motor control performance.

  3. WRS Efficacy Assessment- Time consumption

    Time frame: 6 months after the implantation

    Motor function improvement is validated through cursor control performance metrics, particularly time consumption (total task completion duration). Shorter durations indicate superior motor performance.

  4. Neurological Recovery Assessment

    Time frame: 3, 15, 30, 90, 180 days after implantation

    The International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) scale was used to evaluate overall neurological status. The higher the scale score, the better the overall neurological status.

  5. Changes in Quality of Life

    Time frame: 3, 15, 30, 90, 180 days after implantation

    Variations in the MOS item short from health survey (SF-36) scores were evaluated during both the main study period and long-term follow-up phase (comparing baseline to 6-month post-implantation assessments). The score values directly reflect health status - higher scores indicate better functional outcomes and superior quality of life.

  6. Changes in Cognitive Performance

    Time frame: 3, 15, 30, 90, 180 days after implantation

    Variations in Montreal Cognitive Assessment (MoCA) scores scores were evaluated during both the main study period and long-term follow-up phase (comparing baseline to 6-month post-implantation assessments). Elevated scores are associated with improved cognitive function.

  7. Changes in Psychological Status

    Time frame: 3, 15, 30, 90, 180 days after implantation

    Variations in Patient Health Questionnaire (PHQ-9) scores were evaluated during both the main study period and long-term follow-up phase (comparing baseline to 6-month post-implantation assessments). Higher scores indicate poorer psychological status.

  8. Changes in Anxiety Status

    Time frame: 3, 15, 30, 90, 180 days after implantation

    Variations in Hamilton Anxiety Rating Scale (HAMA) scores were evaluated during both the main study period and long-term follow-up phase (comparing baseline to 6-month post-implantation assessments). Higher scores indicate poorer psychological status.

  9. Changes in Depression Status

    Time frame: 3, 15, 30, 90, 180 days after implantation

    Variations in Hamilton Depression Rating Scale (HAMD) scores were evaluated during both the main study period and long-term follow-up phase (comparing baseline to 6-month post-implantation assessments). Higher scores indicate poorer psychological status.

Study contacts

Contact information is provided by the study sponsor or research team.

Stairmed Clinical team

CONTACT

[email protected]

+86 021-80510178

Sponsors and collaborators

Lead sponsor

Shanghai StairMed Technology Co., Ltd.

Industry

Registry information

Acronym: STAIR

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 25, 2025
Registry last updated
Apr 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.